** Shares of drugmaker Jazz Pharmaceuticals JAZZ.O rise 13.4% to $160 premarket

** Company says its drug, Ziihera, in combination with chemotherapy, met main goals in a late-stage study for the treatment of a type of stomach cancer

** In the study, Ziihera showed meaningful and statistically significant improvements in progression-free and overall survival in patients compared to those on standard of care in combination with chemotherapy - JAZZ

** JAZZ shares rights of the therapy with Zymeworks ZYME.O, shares of which are also up 43.52% premarket

** Co plans to submit a marketing application to the U.S. FDA for this indication in H1 2026

** Ziihera is already approved in the U.S. for the treatment of a type of biliary tract cancer

** As of last close, JAZZ up 14.6% and ZYME up 26.5% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))